FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Charles Sawyers

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Physiology

Genes & Molecular Sequences

Genes, abl

Anatomy

Co-author Network

Publications

TOP 3
Minna D Balbas; Yu Chen; Michael J Evans; Geoffrey L Greene; David J Hosfield; Yang Shen; Philip A Watson; John Wongvipat; Vivek K Arora; Charles L Sawyers
Overcoming mutation-based resistance to antiandrogens with rational drug design.
Michael J Evans; Jason P Holland; Ingo K Mellinghoff; Samuel L Rice; Charles L Sawyers; Carl Campos; Sean D Carlin; Sarah M Cheal; Michael G Doran; Jason S Lewis
Imaging tumor burden in the brain with 89Zr-transferrin.
Nicholas Mitsiades; Chris Sander; Charles L Sawyers; Daniel C Danila; Vijay Kumar Eedunuri; Martin Fleisher; Bin He; Nikolaus Schultz; Clifford Sung; Howard I Scher
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Charles Sawyers (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Minna D Balbas; Yu Chen; Michael J Evans; Geoffrey L Greene; David J Hosfield; Yang Shen; Philip A Watson; John Wongvipat; Vivek K Arora; Charles L Sawyers
Overcoming mutation-based resistance to antiandrogens with rational drug design.
eLife 2013;2():e00499.
2013: Michael J Evans; Jason P Holland; Ingo K Mellinghoff; Samuel L Rice; Charles L Sawyers; Carl Campos; Sean D Carlin; Sarah M Cheal; Michael G Doran; Jason S Lewis
Imaging tumor burden in the brain with 89Zr-transferrin.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013;54(1):90-5.
2012: Nicholas Mitsiades; Chris Sander; Charles L Sawyers; Daniel C Danila; Vijay Kumar Eedunuri; Martin Fleisher; Bin He; Nikolaus Schultz; Clifford Sung; Howard I Scher
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
Cancer research 2012;72(23):6142-52.
2012: Anette Hübner; Maria Karasarides; David J Mulholland; Charles L Sawyers; Claire L Standen; Cathy Tournier; Hong Wu; Tamera Barrett; Julie Cavanagh-Kyros; Hongbo Chi; Richard A Flavell; Dale L Greiner; Roger J Davis
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(30):12046-51.
2012: Haley Hieronymus; Charles L Sawyers
Traversing the genomic landscape of prostate cancer from diagnosis to death.
Nature genetics 2012;44(6):613-4.
2012: Emily H Cheng; Charles L Sawyers
In cancer drug resistance, germline matters too.
Nature medicine 2012;18(4):494-6.
2012: Michael S Glickman; Charles L Sawyers
Converting cancer therapies into cures: lessons from infectious diseases.
Cell 2012;148(6):1089-98.
2011: Daniel C Danila; Martin Fleisher; Glenn Heller; Margaret A Leversha; Hans Lilja; Arturo Molina; Charles L Sawyers; Aseem Anand; Long Cao; Clifford Sung; Howard I Scher
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
European urology 2011;60(5):897-904.
2011: Michael J Evans; Sae Kim; Steven M Larson; Vincent Navarro; Peter Smith-Jones; John Wongvipat; Neil H Bander; Charles L Sawyers
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(23):9578-82.
2011: Natsuko Suwaki; Elsa Vanhecke; Katelyn M Atkins; Manuela Graf; Katherine Swabey; Paul H. Huang; Peter Schraml; Holger Moch; Amy Mulick Cassidy; Daniel Brewer; Bissan Al-Lazikani; Paul Workman; Johann De-Bono; Stan B Kaye; James Larkin; Martin E Gore; Charles L Sawyers; Peter Nelson; Tomasz M Beer; Hao Geng; Lina Gao; David Z Qian; Joshi J Alumkal; Gary Thomas; George V Thomas
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Science translational medicine 2011;3(85):85ra47.
2011: Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Cancer cell 2011;19(5):575-86.
2011: Trever G Bivona; Haley Hieronymus; Joel Parker; Kenneth Chang; Miquel Taron; Rafael Rosell; Philicia Moonsamy; Kimberly Dahlman; Vincent A Miller; Carlota Costa; Gregory Hannon; Charles L Sawyers
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Nature 2011;471(7339):523-6.
2011: Kevin Leder; Jasmine Foo; Mercedes Gorre; Charles L Sawyers; Brian Skaggs; Franziska Michor
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.
PloS one 2011;6(11):e27682.
2011: Nicola J Clegg; Suzana S Couto; John Wongvipat; Haley Hieronymus; Brett S Carver; Barry S Taylor; Katharine Ellwood-Yen; William L Gerald; Chris Sander; Charles L Sawyers
MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors.
PloS one 2011;6(3):e17449.
2010: Philip A Watson; Yinan F Chen; Minna D Balbas; John Wongvipat; Nicholas D Socci; Agnes Viale; Kwanghee Kim; Charles L Sawyers
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(39):16759-65.
2010: Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald
Integrative genomic profiling of human prostate cancer.
Cancer cell 2010;18(1):11-22.
2010: Srinivas Nandana; Katharine Ellwood-Yen; Charles L Sawyers; Marcia Wills; Brandy Weidow; Thomas Case; Valeri Vasioukhin; Robert J Matusik
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
The Prostate 2010;70(6):591-600.
2010: Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Elizabeth Rathkopf; Julia Shelkey; Evan Y Yu; Joshi J Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John L Humm; Steven M Larson; Martin Fleisher; Charles L Sawyers
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet 2010;375(9724):1437-46.
2009: Charles L Sawyers
Shifting paradigms: the seeds of oncogene addiction.
Nature medicine 2009;15(10):1158-61.
2009: Charles L Sawyers
Lessons learned from the development of kinase inhibitors.
Clinical advances in hematology & oncology : H&O 2009;7(9):588-9.
2009: Charles L Sawyers
Finding and drugging the vulnerabilities of RAS-dependent cancers.
Cell 2009;137(5):796-8.
2009: Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Science (New York, N.Y.) 2009;324(5928):787-90.
2009: Jennifer King; Jin Xu; John Wongvipat; Haley Hieronymus; Brett S Carver; David H Leung; Barry S Taylor; Chris Sander; Robert Cardiff; Suzana S Couto; William L Gerald; Charles L Sawyers
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
Nature genetics 2009;41(5):524-6.
2009: Derek S Welsbie; Jin Xu; Yu Chen; Laetitia Borsu; Howard I Scher; Neal Rosen; Charles L Sawyers
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.
Cancer research 2009;69(3):958-66.
2008: Neil P Shah; Corynn Kasap; Christopher Weier; Minna Balbas; John M Nicoll; Eric Bleickardt; Claude Nicaise; Charles L Sawyers
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Cancer cell 2008;14(6):485-93.
2008: Charles L Sawyers
Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address.
The Journal of clinical investigation 2008;118(11):3798-801.
2008: Ren Jie Jin; Yongsoo Lho; Linda Connelly; Yongqing Wang; Xiuping Yu; Leshana Saint Jean; Tom Case; Katharine Ellwood-Yen; Charles L Sawyers; Neil A Bhowmick; Timothy S Blackwell; Fiona E Yull; Robert J Matusik
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.
Cancer research 2008;68(16):6762-9.
2008: Pradip K Majumder; Chiara Grisanzio; Fionnuala O'Connell; Marc Barry; Joseph M Brito; Qing Xu; Isil Guney; Raanan Berger; Paula Herman; Rachel Bikoff; Giuseppe Fedele; Won-Ki Baek; Shunyou Wang; Katharine Ellwood-Yen; Hong Wu; Charles L Sawyers; Sabina Signoretti; William C Hahn; Massimo Loda; William R Sellers
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.
Cancer cell 2008;14(2):146-55.
2008: Yu Chen; Charles L Sawyers; Howard I Scher
Targeting the androgen receptor pathway in prostate cancer.
Current opinion in pharmacology 2008;8(4):440-8.
2008: Charles L Sawyers
The cancer biomarker problem.
Nature 2008;452(7187):548-52.
2008: Charles L Sawyers
Something lost--something gained: the ASCI begins its second century.
The Journal of clinical investigation 2008;118(4):1213-4.
2008: Elizabeth A. Duncan; Christine A Goetz; Sarah J Stein; Katie J Mayo; Brian J Skaggs; Karl Ziegelbauer; Charles L Sawyers; Albert S Baldwin
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Molecular cancer therapeutics 2008;7(2):391-7.
2008: Timothy F Cloughesy; Koji Yoshimoto; Phioanh Nghiemphu; Kevin Brown; Julie Dang; Shaojun Zhu; Teli Hsueh; Yinan Chen; Wei Wang; David Youngkin; Linda M Liau; Neil Martin; Don Becker; Marvin Bergsneider; Albert Lai; Richard Green; Tom Oglesby; Michael Koleto; Jeffrey M. Trent; Steve Horvath; Paul S Mischel; Ingo K Mellinghoff; Charles L Sawyers
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
PLoS medicine 2008;5(1):e8.
2007: William G Kaelin; Charles L Sawyers; Enrico Mihich
Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer.
Cancer research 2007;67(23):11102-5.
2007: Charles L Sawyers
Cancer: mixing cocktails.
Nature 2007;449(7165):993-6.
2007: Charles L Sawyers
Where lies the blame for resistance--tumor or host?
Nature medicine 2007;13(10):1144-5.
2007: Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
The Journal of clinical investigation 2007;117(9):2562-9.
2007: Jing Jiao; Shunyou Wang; Rong Qiao; Igor Vivanco; Philip A Watson; Charles L Sawyers; Hong Wu
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
Cancer research 2007;67(13):6083-91.
2007: J Saldanha; Monique Silvy; N Beaufils; R Arlinghaus; G Barbany; Susan Branford; Jean-Michel Cayuela; Giovanni Cazzaniga; M Gonzalez; David Grimwade; V Kairisto; K Miyamura; M Lawler; Thomas Lion; Elizabeth Macintyre; F-X Mahon; Martin C Muller; M Ostergaard; Heike Pfeifer; Giuseppe Saglio; Charles L Sawyers; Orietta Spinelli; V H J van der Velden; J Q Wang; K Zoi; V Patel; P Phillips; P Matejtschuk; Jean Gabert
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.
Leukemia 2007;21(7):1481-7.
2007: Igor Vivanco; NICOLAOS PALASKAS; Chris Tran; Stephen P Finn; Gad Getz; Norman J Kennedy; Jing Jiao; Joshua Rose; Wanling Xie; Massimo Loda; Todd R Golub; Ingo K Mellinghoff; Roger J Davis; Hong Wu; Charles L Sawyers
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.
Cancer cell 2007;11(6):555-69.
2006: Brian J Skaggs; Mercedes E Gorre; Ann Ryvkin; Michael Raymond Burgess; Yongming Xie; Yun Han; Evangelia Komisopoulou; Lauren M Brown; Joseph A Loo; Elliot M Landaw; Charles L Sawyers; Thomas G Graeber
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(51):19466-71.
2006: Katharine Ellwood-Yen; John Wongvipat; Charles L Sawyers
Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
Cancer research 2006;66(21):10513-6.
2006: Maria Y Wang; Kan V Lu; Shaojun Zhu; Ederlyn Q Dia; Igor Vivanco; Gregory M Shackleford; Webster K Cavenee; Ingo K Mellinghoff; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Cancer research 2006;66(16):7864-9.
2006: Charles L Sawyers
Will kinase inhibitors have a dark side?
The New England journal of medicine 2006;355(3):313-5.
2006: Moshe Talpaz; Neil P Shah; Andrew Lamb; Nicholas J Donato; John Nicoll; Ronald L Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P DeCillis; Charles L Sawyers
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
The New England journal of medicine 2006;354(24):2531-41.
2006: Joya Chandra; Jeannette Tracy; David Loegering; Karen Flatten; Srdan Verstovsek; Miloslav Beran; Mercedes Gorre; Zeev Estrov; Nicholas J Donato; Moshe Talpaz; Charles L Sawyers; Kapil N Bhalla; Judith E Karp; Edward A Sausville; Scott H Kaufmann
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Blood 2006;107(6):2501-6.
2006: Sung Hee Baek; Kenneth A Ohgi; Charles A Nelson; Derek Welsbie; Charlie Chen; Charles L Sawyers; David W Rose; Michael G Rosenfeld
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(9):3100-5.
2006: Jerald P Radich; Hongyue Dai; Mao Mao; Vivian G Oehler; Janell Schelter; Brian J Druker; Charles L Sawyers; Neil Shah; Wendy Stock; Cheryl L Willman; Stephen H Friend; Peter Linsley
Gene expression changes associated with progression and response in chronic myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(8):2794-9.
2006: Matthew Adam Young; Neil P Shah; Luke H Chao; Markus Seeliger; Zdravko V Milanov; William H Biggs; Daniel K Treiber; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart; Charles L Sawyers; John Kuriyan
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Cancer research 2006;66(2):1007-14.
2006: Michael Raymond Burgess; Charles L Sawyers
Treating imatinib-resistant leukemia: the next generation targeted therapies.
TheScientificWorldJournal 2006;6():918-30.
2006: George V Thomas; Chris Tran; Ingo K Mellinghoff; Derek S Welsbie; Emily Chan; Barbara J Fueger; Johannes Czernin; Charles L Sawyers
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
Nature medicine 2006;12(1):122-7.
2005: Philip A Watson; Katharine Ellwood-Yen; Jennifer King; John Wongvipat; Michelle M Lebeau; Charles L Sawyers
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Cancer research 2005;65(24):11565-71.
2005: Shahriar Koochekpour; Yu-Jun Zhuang; Rameen Beroukhim; Chia-Ling Hsieh; Matthias D Hofer; Haiyen E Zhau; Masao Hiraiwa; Daniel Y Pattan; Joy L Ware; Ronald B Luftig; Konrad Sandhoff; Charles L Sawyers; Kenneth Pienta; Mark A Rubin; Robert L Vessella; William R Sellers; Oliver Sartor
Amplification and overexpression of prosaposin in prostate cancer.
Genes, chromosomes & cancer 2005;44(4):351-64.
2005: Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
The New England journal of medicine 2005;353(19):2012-24.
2005: Howard I Scher; Charles L Sawyers
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(32):8253-61.
2005: Charles L Sawyers
Update on the use of imatinib mesylate.
Clinical advances in hematology & oncology : H&O 2005;3(10):757-8.
2005: Todd A Carter; Lisa M Wodicka; Neil P Shah; Anne Marie Velasco; Miles A Fabian; Daniel K Treiber; Zdravko V Milanov; Corey E Atteridge; William H Biggs; Philip T Edeen; Mark Floyd; Julia M Ford; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Shamal A Mehta; Hitesh K Patel; William Pao; Charles L Sawyers; Harold Varmus; Patrick P Zarrinkar; David J Lockhart
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(31):11011-6.
2005: Charles L Sawyers
Calculated resistance in cancer.
Nature medicine 2005;11(8):824-5.
2005: Franziska Michor; Timothy P Hughes; Yoh Iwasa; Susan Branford; Neil P Shah; Charles L Sawyers; Martin A Nowak
Dynamics of chronic myeloid leukaemia.
Nature 2005;435(7046):1267-70.
2005: Jung Hwa Kim; Bogyou Kim; Ling Cai; Hee June Choi; Kenneth A Ohgi; Chris Tran; Charlie Chen; Chin Ha Chung; Otmar Huber; David W Rose; Charles L Sawyers; Michael G Rosenfeld; Sung Hee Baek
Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.
Nature 2005;434(7035):921-6.
2005: Michael Raymond Burgess; Brian J Skaggs; Neil P Shah; Francis Y Lee; Charles L Sawyers
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(9):3395-400.
2005: Su Chu; Helen Xu; Neil P Shah; David S Snyder; Stephen J Forman; Charles L Sawyers; Ravi Bhatia
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Blood 2005;105(5):2093-8.
2005: Christian Waldherr; Ingo K Mellinghoff; Chris Tran; Benjamin S Halpern; Nora Rozengurt; Arash Safaei; Wolfgang A Weber; David B Stout; Nagichettiar Satyamurthy; Jorge Barrio; Michael E Phelps; Daniel H S Silverman; Charles L Sawyers; Johannes Czernin
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(1):114-20.
2005: Thomas G Graeber; Charles L Sawyers
Cross-species comparisons of cancer signaling.
Nature genetics 2005;37(1):7-8.
2004: George V Thomas; Steve Horvath; Bradley L Smith; Katherine Crosby; Lori A Lebel; Matthew Schrage; Jonathan Said; Jean de Kernion; Robert E Reiter; Charles L Sawyers
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8351-6.
2004: Charles L Sawyers
Targeted cancer therapy.
Nature 2004;432(7015):294-7.
2004: Ingo K Mellinghoff; Igor Vivanco; Andrew Kwon; Chris Tran; John Wongvipat; Charles L Sawyers
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.
Cancer cell 2004;6(5):517-27.
2004: Catriona H M Jamieson; Laurie Ailles; Scott J Dylla; Manja Muijtjens; Carol Jones; James L Zehnder; Jason Gotlib; Kevin Li; Markus G Manz; Armand Keating; Charles L Sawyers; Irving L Weissman
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
The New England journal of medicine 2004;351(7):657-67.
2004: Neil P Shah; Chris Tran; Francis Y Lee; Ping Chen; Derek Norris; Charles L Sawyers
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Science (New York, N.Y.) 2004;305(5682):399-401.
2004: Ingo K Mellinghoff; Charles L Sawyers
TORward AKTually useful mouse models.
Nature medicine 2004;10(6):579-80.
2004: Bin Peng; Michael Hayes; Debra Resta; Amy Racine-Poon; Brian J Druker; Moshe Talpaz; Charles L Sawyers; Marianne Rosamilia; John Ford; Peter Lloyd; Renaud Capdeville
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):935-42.
2004: Joseph Gera; Ingo K Mellinghoff; Yijiang Shi; Matthew B Rettig; Chris Tran; Jung-hsin Hsu; Charles L Sawyers; Alan K Lichtenstein
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.
The Journal of biological chemistry 2004;279(4):2737-46.
2004: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert L Vessella; Michael G Rosenfeld; Charles L Sawyers
Molecular determinants of resistance to antiandrogen therapy.
Nature medicine 2004;10(1):33-9.
2003: Charles L Sawyers
Opportunities and challenges in the development of kinase inhibitor therapy for cancer.
Genes & development 2003;17(24):2998-3010.
2003: Charles L Sawyers
Will mTOR inhibitors make it as cancer drugs?
Cancer cell 2003;4(5):343-8.
2003: Neil P Shah; Charles L Sawyers
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Oncogene 2003;22(47):7389-95.
2003: Katharine Ellwood-Yen; Thomas G Graeber; John Wongvipat; M Luisa Iruela-Arispe; JianFeng Zhang; Robert J Matusik; George V Thomas; Charles L Sawyers
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
Cancer cell 2003;4(3):223-38.
2003: Ravi Bhatia; Melissa Holtz; Ning Niu; Rachel Gray; David S Snyder; Charles L Sawyers; Daniel A Arber; Marilyn L Slovak; Stephen J Forman
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Blood 2003;101(12):4701-7.
2003: Gheeyoung Choe; Steve Horvath; Timothy F Cloughesy; Katherine Crosby; David Seligson; Aarno Palotie; Landon Inge; Bradley L Smith; Charles L Sawyers; Paul S Mischel
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Cancer research 2003;63(11):2742-6.
2003: David R Huron; Mercedes E Gorre; Alan J Kraker; Charles L Sawyers; Neal Rosen; Mark M Moasser
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1267-73.
2003: Honghao Yang; Frank Berger; Chris Tran; Sanjiv S Gambhir; Charles L Sawyers
MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts.
The Prostate 2003;55(1):39-47.
2002: Mercedes E Gorre; Katharine Ellwood-Yen; Gabriela Chiosis; Neal Rosen; Charles L Sawyers
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Blood 2002;100(8):3041-4.
2002: Ingo K Mellinghoff; Chris Tran; Charles L Sawyers
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
Cancer research 2002;62(18):5254-9.
2002: Oliver G Ottmann; Brian J Druker; Charles L Sawyers; John M Goldman; Josy Reiffers; Richard T Silver; Sante Tura; Thomas Fischer; Michael W N Deininger; Charles Alan Schiffer; Michele Baccarani; Alois Gratwohl; Andreas Hochhaus; Dieter Hoelzer; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Stephen G O'Brien
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood 2002;100(6):1965-71.
2002: Frank Berger; Yu-Po Lee; Andreas M Loening; Arion F Chatziioannou; Stephen J Freedland; Richard M Leahy; Jay R Lieberman; Arie S Belldegrun; Charles L Sawyers; Sanjiv S Gambhir
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease.
European journal of nuclear medicine and molecular imaging 2002;29(9):1225-36.
2002: Ingo K Mellinghoff; Charles L Sawyers
The emergence of resistance to targeted cancer therapeutics.
Pharmacogenomics 2002;3(5):603-23.
2002: Sari Laitinen; Ritva Karhu; Charles L Sawyers; Robert L Vessella; Tapio Visakorpi
Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization.
Genes, chromosomes & cancer 2002;35(1):66-73.
2002: Charles L Sawyers
Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3568-9.
2002: Patricia Hess; German Pihan; Charles L Sawyers; Richard A Flavell; Roger J Davis
Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts.
Nature genetics 2002;32(1):201-5.
2002: Sergei Roumiantsev; Neil P Shah; Mercedes E Gorre; John Nicoll; Bradley B Brasher; Charles L Sawyers; Richard A Van Etten
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(16):10700-5.
2002: Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Cancer cell 2002;2(2):117-25.
2002: Ronald L Paquette; NC Hsu; Jonathan Said; M Mohammed; Nagesh P Rao; G Shih; Gary J Schiller; Charles L Sawyers; John A Glaspy
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.
Leukemia 2002;16(8):1484-9.
2002: Miranda Thomas; Richard Laura; Karin Hepner; Ernesto Guccione; Charles L Sawyers; Laurence A Lasky; Lawrence Banks
Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation.
Oncogene 2002;21(33):5088-96.
2002: Sigal Gery; Charles L Sawyers; David B Agus; Jonathan W Said; H Phillip Koeffler
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells.
Oncogene 2002;21(31):4739-46.
2002: Rita M Braziel; Teresa M Launder; Brian J Druker; Susan B Olson; R Ellen Magenis; Michael J Mauro; Charles L Sawyers; Ronald L Paquette; Michael O'Dwyer
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Blood 2002;100(2):435-41.
2002: Igor Vivanco; Charles L Sawyers
The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
Nature reviews. Cancer 2002;2(7):489-501.
2002: Mercedes E Gorre; Charles L Sawyers
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.
Current opinion in hematology 2002;9(4):303-7.
2002: Charles L Sawyers
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
Cancer cell 2002;1(5):413-5.
2002: Melissa Holtz; Marilyn L Slovak; Feiyu Zhang; Charles L Sawyers; Stephen J Forman; Ravi Bhatia
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
Blood 2002;99(10):3792-800.
2002: Charlie D Chen; Charles L Sawyers
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer.
Molecular and cellular biology 2002;22(8):2862-70.
2002: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; françois guilhot; Charles Alan Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
2002: Charles L Sawyers; Edward A Sausville
Overview: the art of cancer drug screening: molecular target versus milieu-based screens.
Current opinion in investigational drugs (London, England : 2000) 2002;3(3):478-81.
2002: Charles L Sawyers
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Cancer cell 2002;1(1):13-5.
2002: Charles L Sawyers
Rational therapeutic intervention in cancer: kinases as drug targets.
Current opinion in genetics & development 2002;12(1):111-5.
2001: MS Neshat; Ingo K Mellinghoff; Chris Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; Charles L Sawyers
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(18):10314-9.
2001: Katrina Podsypanina; R T Lee; C Politis; I Hennessy; A Crane; Janusz Puc; MS Neshat; Hong Wang; Lin Yang; J Gibbons; P Frost; Valley C Dreisbach; J Blenis; Zbigniew Gaciong; P Fisher; Charles L Sawyers; L Hedrick-Ellenson; Ramon Parsons
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(18):10320-5.
2001: Mercedes E Gorre; M Mohammed; K Ellwood; NC Hsu; Ronald L Paquette; P Nagesh Rao; Charles L Sawyers
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Science (New York, N.Y.) 2001;293(5531):876-80.
2001: Kunihiro Tsukasaki; Carl W Miller; E Greenspun; S Eshaghian; H Kawabata; T Fujimoto; Masao Tomonaga; Charles L Sawyers; Jonathan W Said; H Phillip Koeffler
Mutations in the mitotic check point gene, MAD1L1, in human cancers.
Oncogene 2001;20(25):3301-5.
2001: Gary J Schiller; S Wong; T Lowe; G Snead; Ronald L Paquette; Charles L Sawyers; M Wolin; L Kunkel; Lena H Ting; G Li; Mary Territo
Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission.
Leukemia 2001;15(5):757-63.
2001: Brian J Druker; Charles L Sawyers; Andrew Lamb; Debra Resta; S F Reese; J M Ford; Renaud Capdeville; Moshe Talpaz
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
The New England journal of medicine 2001;344(14):1038-42.
2001: Brian J Druker; Moshe Talpaz; Debra Resta; B Peng; Elisabeth Buchdunger; J M Ford; NB Lydon; Andrew Lamb; Renaud Capdeville; S Ohno-Jones; Charles L Sawyers
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
The New England journal of medicine 2001;344(14):1031-7.
2001: Neil P Shah; Charles L Sawyers
Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
Current opinion in investigational drugs (London, England : 2000) 2001;2(3):422-3.
2000: Young E Whang; Chris Tran; C Henderson; R G Syljuasen; Nora Rozengurt; william mcbride; Charles L Sawyers
c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(10):5486-91.
2000: X Wu; K Hepner; S Castelino-Prabhu; D Do; M B Kaye; Xiu-Juan Yuan; J Wood; C Ross; Charles L Sawyers; Young E Whang
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(8):4233-8.
2000: MS Neshat; Arthur B Raitano; Hong-Gang Wang; J C Reed; Charles L Sawyers
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.
Molecular and cellular biology 2000;20(4):1179-86.
1999: N Craft; C Chhor; Chris Tran; Arie Belldegrun; Jean B deKernion; Owen N Witte; Jonathan Said; Robert E Reiter; Charles L Sawyers
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.
Cancer research 1999;59(19):5030-6.
1999: W Huang; Y Shostak; Paul Tarr; Charles L Sawyers; Michael Carey
Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer.
The Journal of biological chemistry 1999;274(36):25756-68.
1999: Maria T Abreu-Martin; A Chari; AA Palladino; N A Craft; Charles L Sawyers
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer.
Molecular and cellular biology 1999;19(7):5143-54.
1999: Gary J Schiller; M Lee; Ronald L Paquette; Charles L Sawyers; F Khoubian; Mary Territo
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.
Leukemia & lymphoma 1999;33(5-6):475-84.
1999: Charles L Sawyers
Chronic myeloid leukemia.
The New England journal of medicine 1999;340(17):1330-40.
1999: Charles L Sawyers; Brian J Druker
Tyrosine kinase inhibitors in chronic myeloid leukemia.
The cancer journal from Scientific American 1999;5(2):63-9.
1999: N Craft; Y Shostak; Michael Carey; Charles L Sawyers
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.
Nature medicine 1999;5(3):280-5.
1998: X Wu; K Senechal; MS Neshat; Young E Whang; Charles L Sawyers
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(26):15587-91.
1998: Charles L Sawyers
Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes.
Leukemia research 1998;22(12):1113-22.
1998: K Senechal; C Heaney; Brian J Druker; Charles L Sawyers
Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.
Molecular and cellular biology 1998;18(9):5082-90.
1998: Young E Whang; X Wu; Charles L Sawyers
Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene.
Journal of the National Cancer Institute 1998;90(11):859-61.
1998: Young E Whang; X Wu; H Suzuki; Robert E Reiter; Chris Tran; Robert L Vessella; Jonathan W Said; William B Isaacs; Charles L Sawyers
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(9):5246-50.
1998: N Craft; Charles L Sawyers
Mechanistic concepts in androgen-dependence of prostate cancer.
Cancer metastasis reviews 1998;17(4):421-7.
1997: Arthur B Raitano; Young E Whang; Charles L Sawyers
Signal transduction by wild-type and leukemogenic Abl proteins.
Biochimica et biophysica acta 1997;1333(3):F201-16.
1997: Gary J Schiller; M Lee; T Miller; Michael Lill; A Mittal-Henkle; Ronald L Paquette; Charles L Sawyers; Mary Territo
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission.
Leukemia 1997;11(9):1533-9.
1997: M Dickens; J S Rogers; J Cavanagh; Arthur B Raitano; Z Xia; J R Halpern; Michael E Greenberg; Charles L Sawyers; Roger J Davis
A cytoplasmic inhibitor of the JNK signal transduction pathway.
Science (New York, N.Y.) 1997;277(5326):693-6.
1997: Charles L Sawyers
Signal transduction pathways involved in BCR-ABL transformation.
Baillière's clinical haematology 1997;10(2):223-31.
1997: K A Klein; Robert E Reiter; J Redula; H Moradi; X L Zhu; A R Brothman; D J Lamb; M Marcelli; Arie Belldegrun; O N Witte; Charles L Sawyers
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.
Nature medicine 1997;3(4):402-8.
1997: Charles L Sawyers
Molecular genetics of acute leukaemia.
Lancet 1997;349(9046):196-200.
1996: K Senechal; Charles L Sawyers
Signal transduction-based strategies for the treatment of chronic myelogenous leukemia.
Molecular medicine today 1996;2(12):503-9.
1996: K Senechal; J Halpern; Charles L Sawyers
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.
The Journal of biological chemistry 1996;271(38):23255-61.
1996: Ke Shuai; J Halpern; J ten Hoeve; X Rao; Charles L Sawyers
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Oncogene 1996;13(2):247-54.
1995: A B Raitano; J R Halpern; T M Hambuch; Charles L Sawyers
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(25):11746-50.
1995: A Goga; Xueli Liu; T M Hambuch; K Senechal; E Major; A J Berk; Owen N Witte; Charles L Sawyers
p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase.
Oncogene 1995;11(4):791-9.
1994: R W Hathorn; Cho-Lea Tso; R Kaboo; Shen Pang; Robert Figlin; Charles L Sawyers; Jean B deKernion; A Belldegrun
In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer.
Cancer 1994;74(7):1904-11.
1994: Charles L Sawyers; C T Denny
Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about.
Cell 1994;77(2):171-3.
1994: Daniel E H Afar; A Goga; Jami McLaughlin; Owen N Witte; Charles L Sawyers
Differential complementation of Bcr-Abl point mutants with c-Myc.
Science (New York, N.Y.) 1994;264(5157):424-6.
1994: Charles L Sawyers; Jami McLaughlin; A Goga; M Havlik; O Witte
The nuclear tyrosine kinase c-Abl negatively regulates cell growth.
Cell 1994;77(1):121-31.
1994: Daniel E H Afar; A Goga; L Cohen; Charles L Sawyers; Jami McLaughlin; R N Mohr; Owen N Witte
Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL.
Cold Spring Harbor symposia on quantitative biology 1994;59():589-94.
1993: Charles L Sawyers
The role of myc in transformation by BCR-ABL.
Leukemia & lymphoma 1993;11 Suppl 1():45-6.
1993: Charles L Sawyers
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
Leukemia & lymphoma 1993;11 Suppl 2():101-3.
1992: Charles L Sawyers; W Callahan; Owen N Witte
Dominant negative MYC blocks transformation by ABL oncogenes.
Cell 1992;70(6):901-10.
1992: Charles L Sawyers; M L Gishizky; S Quan; David W Golde; Owen N Witte
Propagation of human blastic myeloid leukemias in the SCID mouse.
Blood 1992;79(8):2089-98.
1992: Charles L Sawyers; David W Golde; S Quan; Stephen D Nimer
Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia.
Cancer 1992;69(6):1342-6.
1992: Charles L Sawyers
The bcr-abl gene in chronic myelogenous leukaemia.
Cancer surveys 1992;15():37-51.
1991: Charles L Sawyers; C T Denny; Owen N Witte
Leukemia and the disruption of normal hematopoiesis.
Cell 1991;64(2):337-50.
1990: Charles L Sawyers; L Timson; E S Kawasaki; Steven S Clark; Owen N Witte; Richard Champlin
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(2):563-7.